TY - JOUR
T1 - Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
AU - Böcskei, R.M.
AU - Benczúr, B.
AU - Losonczy, G.
AU - Illyés, M.
AU - Cziráki, A.
AU - Müller, V.
AU - Bohács, A.
AU - Bikov, A.
N1 - Export Date: 10 July 2019
CODEN: LUNGD
Correspondence Address: Böcskei, R.M.; Department of Pulmonology, Semmelweis University, Diós árok Street. 1/c, Hungary; email: [email protected]
References: Vogelmeier, C.F., Criner, G.J., Martinez, F.J., Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD executive summary (2017) Eur Respir J; Barnes, P.J., Burney, P.G., Silverman, E.K., Celli, B.R., Vestbo, J., Wedzicha, J.A., Wouters, E.F., Chronic obstructive pulmonary disease (2015) Nat Rev Dis Primers, 1, p. 15076; Bourdin, A., Burgel, P.R., Chanez, P., Garcia, G., Perez, T., Roche, N., Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities (2009) Eur Respir Rev, 18 (114), pp. 198-212; Coxson, H.O., Dirksen, A., Edwards, L.D., The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study (2013) Lancet Respir Med, 1 (2), pp. 129-136; Packard, R.R., Libby, P., Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction (2008) Clin Chem, 54 (1), pp. 24-38; Thuno, M., Macho, B., Eugen-Olsen, J., suPAR: the molecular crystal ball (2009) Dis Markers, 27 (3), pp. 157-172; Blasi, F., Carmeliet, P., uPAR: a versatile signalling orchestrator (2002) Nat Rev Mol Cell Biol, 3 (12), pp. 932-943; Gustafsson, A., Ajeti, V., Ljunggren, L., Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels (2011) Biomark Insights, 6, pp. 119-125; Donadello, K., Scolletta, S., Covajes, C., suPAR as a prognostic biomarker in sepsis (2012) BMC Med, 10, p. 2; Eugen-Olsen, J., suPAR—a future risk marker in bacteremia (2011) J Intern Med, 270 (1), pp. 29-31; Gozdzik, W., Adamik, B., Gozdzik, A., Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use (2014) PLoS ONE, 9 (6); Gumus, A., Altintas, N., Cinarka, H., Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD (2015) Int J Chron Obstruct Pulmon Dis, 10, pp. 357-365; AboEl-Magd, G.H., Mabrouk, M.M., Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD (2018) J Bras Pneumol, 44 (1), pp. 36-41; Can, U., Guzelant, A., Yerlikaya, F.H., The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease (2014) J Investig Med, 62 (7), pp. 938-943; Wang, H., Yang, T., Li, D., Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease (2016) Int J Chron Obstruct Pulmon Dis, 11, pp. 2369-2376; Miller, M.R., Hankinson, J., Brusasco, V., Standardisation of spirometry (2005) Eur Respir J, 26 (2), pp. 319-338; Horvath, I.G., Nemeth, A., Lenkey, Z., Invasive validation of a new oscillometric device (arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity (2010) J Hypertens, 28 (10), pp. 2068-2075; Baulmann, J., Schillings, U., Rickert, S., A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods (2008) J Hypertens, 26 (3), pp. 523-528; Nemeth, Z., Moczar, K., Deak, G., Evaluation of the tensioday ambulatory blood pressure monitor according to the protocols of the British Hypertension Society and the Association for the Advancement of Medical Instrumentation (2002) Blood Press Monit, 7 (3), pp. 191-197. , PID: 12131077; Sugawara, J., Hayashi, K., Yokoi, T., Age-associated elongation of the ascending aorta in adults (2008) JACC Cardiovasc Imaging, 1 (6), pp. 739-748; Faul, F., Erdfelder, E., Buchner, A., Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses (2009) Behav Res Methods, 41 (4), pp. 1149-1160; Ivancso, I., Toldi, G., Bohacs, A., Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy (2013) PLoS ONE, 8 (4); Bikov, A., Horvath, A., Tomisa, G., Changes in the burden of comorbidities in patients with COPD and Asthma-COPD Overlap according to the GOLD 2017 Recommendations (2018) Lung; Bhatt, S.P., Dransfield, M.T., Chronic obstructive pulmonary disease and cardiovascular disease (2013) Transl Res, 162 (4), pp. 237-251; Tuleta, I., Farrag, T., Busse, L., High prevalence of COPD in atherosclerosis patients (2017) Int J Chron Obstruct Pulmon Dis, 12, pp. 3047-3053; Ambrosino, P., Lupoli, R., Iervolino, S., Clinical assessment of endothelial function in patients with chronic obstructive pulmonary disease: a systematic review with meta-analysis (2017) Internal Emerg Med, 12 (6), pp. 877-885; Larsen, F.F., Petersen, J.A., Novel biomarkers for sepsis: a narrative review (2017) Eur J Internal Med, 45, pp. 46-50; Pawlak, K., Mysliwiec, M., Pawlak, D., The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients (2008) Thromb Res, 122 (3), pp. 328-335; Fuhrman, B., The urokinase system in the pathogenesis of atherosclerosis (2012) Atherosclerosis, 222 (1), pp. 8-14; Steins, M.B., Padro, T., Schwaenen, C., Ruiz, S., Mesters, R.M., Berdel, W.E., Kienast, J., Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions (2004) Blood Coagul Fibrinolysis, 15 (5), pp. 383-391. , PID: 15205586; Sehestedt, T., Lyngbaek, S., Eugen-Olsen, J., Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events (2011) Atherosclerosis, 216 (1), pp. 237-243; Persson, M., Ostling, G., Smith, G., Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease (2014) Stroke, 45 (1), pp. 18-23; Sorensen, M.H., Gerke, O., Eugen-Olsen, J., Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects (2014) Atherosclerosis, 237 (1), pp. 60-66; Hodges, G.W., Bang, C.N., Wachtell, K., suPAR: a new biomarker for cardiovascular disease? (2015) Can J Cardiol, 31 (10), pp. 1293-1302; Lyngbaek, S., Sehestedt, T., Marott, J.L., CRP and suPAR are differently related to anthropometry and subclinical organ damage (2013) Int J Cardiol, 167 (3), pp. 781-785; Zemans, R.L., Jacobson, S., Keene, J., Multiple biomarkers predict disease severity, progression and mortality in COPD (2017) Respir Res, 18 (1), p. 117; Dickens, J.A., Miller, B.E., Edwards, L.D., COPD association and repeatability of blood biomarkers in the ECLIPSE cohort (2011) Respir Res, 12, p. 146; Miller, J., Edwards, L.D., Agusti, A., Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort (2013) Respir Res, 107 (9), pp. 1376-1384; Agusti, A., Edwards, L.D., Rennard, S.I., Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype (2012) PLoS ONE, 7 (5); O’Rourke, M.F., Hashimoto, J., Mechanical factors in arterial aging: a clinical perspective (2007) J Am Coll Cardiol, 50 (1), pp. 1-13; Botha, S., Fourie, C.M., Schutte, R., Associations of suPAR with lifestyle and cardiometabolic risk factors (2014) Eur J Clin Investig, 44 (7), pp. 619-626; Eugen-Olsen, J., Ladelund, S., Sorensen, L.T., Plasma suPAR is lowered by smoking cessation: a randomized controlled study (2016) Eur J Clin Investig, 46 (4), pp. 305-311
PY - 2019/2/28
Y1 - 2019/2/28
N2 - Introduction: Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced systemic inflammation and increased risk for atherosclerosis, however, studies analysing the circulating suPAR levels in COPD are contradictory. The aim of the study was to investigate plasma suPAR concentrations together with markers of arterial stiffness in COPD. Materials and Methods: Twenty-four patients with COPD and 18 non-COPD, control subjects participated in the study. Plasma suPAR was measured, together with lung volumes, symptom burden, exacerbation history, markers of arterial stiffness and soluble inflammatory biomarkers, such as endothelin-1, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6). Results: Plasma suPAR levels were higher in COPD (2.84 ± 0.67 ng/ml vs. 2.41 ± 0.57 ng/ml, p = 0.03) and were related to lung function measured with FEV 1 (r = − 0.65, p < 0.01) and symptom burden determined with the modified Medical Research Council questionnaire (r = 0.55, p < 0.05). Plasma suPAR concentrations correlated with various measures of arterial stiffness in all subjects, but only with ejection duration in COPD (r = − 0.44, p = 0.03). Conclusions: Plasma suPAR levels are elevated in COPD and relate to arterial stiffness. Our results suggest that suPAR may be a potential link between COPD and atherosclerosis. © 2019, The Author(s).
AB - Introduction: Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced systemic inflammation and increased risk for atherosclerosis, however, studies analysing the circulating suPAR levels in COPD are contradictory. The aim of the study was to investigate plasma suPAR concentrations together with markers of arterial stiffness in COPD. Materials and Methods: Twenty-four patients with COPD and 18 non-COPD, control subjects participated in the study. Plasma suPAR was measured, together with lung volumes, symptom burden, exacerbation history, markers of arterial stiffness and soluble inflammatory biomarkers, such as endothelin-1, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6). Results: Plasma suPAR levels were higher in COPD (2.84 ± 0.67 ng/ml vs. 2.41 ± 0.57 ng/ml, p = 0.03) and were related to lung function measured with FEV 1 (r = − 0.65, p < 0.01) and symptom burden determined with the modified Medical Research Council questionnaire (r = 0.55, p < 0.05). Plasma suPAR concentrations correlated with various measures of arterial stiffness in all subjects, but only with ejection duration in COPD (r = − 0.44, p = 0.03). Conclusions: Plasma suPAR levels are elevated in COPD and relate to arterial stiffness. Our results suggest that suPAR may be a potential link between COPD and atherosclerosis. © 2019, The Author(s).
KW - Arterial stiffness
KW - Cardiovascular risk
KW - COPD
KW - IL-6
KW - SuPAR
U2 - 10.1007/s00408-019-00211-w
DO - 10.1007/s00408-019-00211-w
M3 - Article
SN - 0341-2040
JO - Lung
JF - Lung
ER -
